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Accuracy of Patient Health Questionnaire-9 (PHQ-9) for 
 screening to detect major depression: individual participant  
data meta-analysis
Brooke Levis,1 Andrea Benedetti,2 Brett D Thombs,1 on behalf of the DEPRESsion Screening 
Data (DEPRESSD) Collaboration
ABSTRACT
OBJECTIVE
To determine the accuracy of the Patient Health 
Questionnaire-9 (PHQ-9) for screening to detect major 
depression.
DESIGN
Individual participant data meta-analysis.
DATA SOURCES
Medline, Medline In-Process and Other Non-Indexed 
Citations, PsycINFO, and Web of Science (January 
2000-February 2015).
INCLUSION CRITERIA
Eligible studies compared PHQ-9 scores with major 
depression diagnoses from validated diagnostic 
interviews. Primary study data and study level data 
extracted from primary reports were synthesized. 
For PHQ-9 cut-off scores 5-15, bivariate random 
effects meta-analysis was used to estimate pooled 
sensitivity and specificity, separately, among studies 
that used semistructured diagnostic interviews, 
which are designed for administration by clinicians; 
fully structured interviews, which are designed 
for lay administration; and the Mini International 
Neuropsychiatric (MINI) diagnostic interviews, a brief 
fully structured interview. Sensitivity and specificity 
were examined among participant subgroups and, 
separately, using meta-regression, considering all 
subgroup variables in a single model.
RESULTS
Data were obtained for 58 of 72 eligible studies 
(total n=17 357; major depression cases n=2312). 
Combined sensitivity and specificity was maximized 
at a cut-off score of 10 or above among studies 
using a semistructured interview (29 studies, 6725 
participants; sensitivity 0.88, 95% confidence interval 
0.83 to 0.92; specificity 0.85, 0.82 to 0.88). Across 
cut-off scores 5-15, sensitivity with semistructured 
interviews was 5-22% higher than for fully structured 
interviews (MINI excluded; 14 studies, 7680 
participants) and 2-15% higher than for the MINI (15 
studies, 2952 participants). Specificity was similar 
across diagnostic interviews. The PHQ-9 seems to be 
similarly sensitive but may be less specific for younger 
patients than for older patients; a cut-off score of 10 
or above can be used regardless of age..
CONCLUSIONS
PHQ-9 sensitivity compared with semistructured 
diagnostic interviews was greater than in previous 
conventional meta-analyses that combined reference 
standards. A cut-off score of 10 or above maximized 
combined sensitivity and specificity overall and for 
subgroups.
REGISTRATION
PROSPERO CRD42014010673.
Introduction
Screening for depression refers to the use of a 
depression screening questionnaire to identify patients 
who may have depression but have not been identified. 
When screening programs are recommended, 
clinicians are advised to administer a depression 
symptom questionnaire and to use a pre-identified 
cut-off threshold to classify patients as having positive 
or negative screening results. Those with positive 
screening results can then be evaluated to determine 
whether they have depression and, if appropriate, 
should be offered treatment.1 2
The Patient Health Questionnaire-9 (PHQ-9) 
is a nine item questionnaire designed to screen 
for depression in primary care and other medical 
settings.3-7 The standard cut-off score for screening to 
identify possible major depression is 10 or above,3-7 
which was established in the first study on the PHQ-9 
(total n=580, major depression n=41).3 5
A conventional PHQ-9 meta-analysis from 2015 
(36 studies, 21 292 participants) evaluated sensitivity 
and specificity for cut-off scores 7-15 by combining 
accuracy results for each cut-off score that were 
published in included primary studies.8 Pooled 
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sensitivity for the standard cut-off score of 10 was 
0.78 (95% confidence interval 0.70 to 0.84), and 
pooled specificity was 0.87 (0.84 to 0.90). Incomplete 
reporting of results from cut-off scores other than 10 
in the primary studies that were included, however, 
resulted in cut-off score ranges in which sensitivity 
implausibly increased as cut-off scores increased.8 
This suggested possible selective cut-off reporting 
in some primary studies to maximize accuracy.8  9 
Additional limitations included the inability to assess 
differences across patient subgroups, as subgroup 
results were not reported in primary studies; the 
inability to exclude participants already diagnosed 
as having or being treated for depression, who 
would not be screened in practice but were included 
in many primary studies10  11; and the combining of 
accuracy estimates without differentiating between 
reference standards.12 Semistructured diagnostic 
interviews (for example, Structured Clinical Interview 
for DSM Disorders (SCID)13) are intended to be used 
by experienced diagnosticians and require clinical 
judgment. Fully structured interviews (for example, 
Composite International Diagnostic Interview 
(CIDI)14) are fully scripted and designed to be 
administered by lay interviewers to reduce the cost 
of employing trained clinical interviewers; they are 
intended to achieve a high level of standardization 
but may sacrifice accuracy.15-18 The Mini International 
Neuropsychiatric Interview (MINI) is fully structured 
but was designed for very rapid administration and 
described by its authors as being overinclusive as 
a result.19  20 In a recent analysis, controlling for 
depressive symptom scores, we found that the MINI 
classified approximately twice as many participants 
as having major depression as other fully structured 
interviews. Compared with semistructured interviews, 
fully structured interviews (MINI excluded) classified 
more patients with low symptom scores but fewer 
patients with high symptom scores as having major 
depression.12
Individual participant data meta-analysis involves 
a standard systematic review, then synthesis of 
participant level data from primary studies rather than 
summary results from study reports.21 Advantages 
include the ability to do subgroup analyses not reported 
in primary studies, the ability to report results from all 
relevant cut-off scores from all included studies, and 
the ability to exclude participants already diagnosed 
as having or treated for depression who would not be 
screened in practice.
The objectives of this study were to use individual 
participant data meta-analysis to evaluate the 
diagnostic accuracy of the PHQ-9 screening tool 
among studies using semistructured, fully structured 
(MINI excluded), and MINI diagnostic interviews as 
reference standards, separately, with priority given to 
semistructured interview results; among participants 
not diagnosed as having or receiving treatment for 
a mental health problem; and among participant 
subgroups based on age, sex, country human 
development index, and recruitment setting.
Methods
This individual participant data meta-analysis was 
registered in PROSPERO (CRD42014010673), a 
protocol was published,22 and results were reported 
following PRISMA-DTA and PRISMA-IPD reporting 
guidelines.23 24
Search strategy
A medical librarian searched Medline, Medline 
In-Process and Other Non-Indexed Citations via 
Ovid, PsycINFO, and Web of Science (January 1, 
2000-February 7, 2015) on February 7, 2015, using 
a peer reviewed search strategy (supplementary 
methods A).25 The search was limited to 2000 forward 
because the PHQ-9 was published in 2001.3 We also 
reviewed reference lists of relevant reviews and 
queried contributing authors about non-published 
studies. Search results were uploaded into RefWorks 
(RefWorks-COS, Bethesda, MD, USA). After de-
duplication, unique citations were uploaded into 
DistillerSR (Evidence Partners, Ottawa, Canada) for 
storing and tracking of search results.
Identification of eligible studies
Datasets from articles in any language were eligible for 
inclusion if they included diagnostic classification for 
current major depressive disorder or major depressive 
episode on the basis of a validated semistructured or 
fully structured interview conducted within two weeks 
of PHQ-9 administration among participants aged 18 
years or over who were not recruited from youth or 
psychiatric settings or because they were identified 
as having symptoms of depression. We required the 
diagnostic interviews and PHQ-9 to be administered 
within two weeks of each other because the Diagnostic 
and Statistical Manual of Mental Disorders (DSM) and 
international classification of diseases (ICD) diagnostic 
criteria for major depression specify that symptoms 
must have been present in the previous two weeks. We 
excluded patients from psychiatric settings and those 
already identified as having symptoms of depression 
because screening is done to identify previously 
unrecognized cases.
Datasets in which not all participants were eligible 
were included if primary data allowed selection of 
eligible participants. For defining major depression, 
we considered major depressive disorder or major 
depressive episode based on the DSM or ICD criteria. 
If more than one was reported, we prioritized major 
depressive episode over major depressive disorder, as 
screening would attempt to detect depressive episodes 
and further interview would determine whether the 
episode was related to major depressive disorder or 
bipolar disorder, and DSM over ICD. Across all studies, 
there were 23 discordant diagnoses depending on 
classification prioritization (0.1% of participants).
Two investigators independently reviewed titles 
and abstracts for eligibility. If either deemed a study 
potentially eligible, two investigators did full text 
review independently, with disagreements resolved 
by consensus, consulting a third investigator when 
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necessary. We consulted translators for languages 
other than those in which team members were fluent.
Data extraction, contribution, and synthesis
We invited authors of eligible datasets to contribute 
de-identified primary data. Two investigators 
independently extracted country, recruitment setting 
(non-medical, primary care, inpatient specialty, 
outpatient specialty), and diagnostic interview from 
published reports, with disagreements resolved by 
consensus. We categorized countries as “very high,” 
“high,” or “low-medium” development on the basis 
of the United Nations’ human development index.26 
Participant level data included age, sex, major 
depression status, current mental health diagnosis or 
treatment, and PHQ-9 scores. In two primary studies, 
multiple recruitment settings were included, so 
recruitment setting was coded at the participant level. 
When datasets included statistical weights to reflect 
sampling procedures, we used the weights provided. 
For studies in which sampling procedures merited 
weighting but the original study did not weight, 
we constructed weights by using inverse selection 
probabilities. Weighting occurred, for instance, 
when a diagnostic interview was administered to all 
participants with positive screens and a random subset 
of participants with negative screens.
We converted individual participant data to a 
standard format and synthesized them into a single 
dataset with study level data. We compared published 
participant characteristics and diagnostic accuracy 
results with results from raw datasets and resolved 
any discrepancies in consultation with the original 
investigators.
Two investigators assessed risk of bias of included 
studies independently, on the basis of the primary 
publications, using the Quality Assessment of 
Diagnostic Accuracy Studies-2 tool (supplementary 
methods B).27 Discrepancies were resolved by 
consensus.
Statistical analyses
We did three main sets of analyses. Firstly, we estimated 
sensitivity and specificity across PHQ-9 cut-off scores 
5-15 for studies with semistructured (SCID,13 Schedules 
for Clinical Assessment in Neuropsychiatry,28 
Depression Interview and Structured Hamilton29), fully 
structured (MINI excluded; CIDI,14 Clinical Interview 
Schedule-Revised,30 Diagnostic Interview Schedule31), 
and MINI19  20 reference standards, separately. 
Secondly, for each reference standard category, we 
estimated sensitivity and specificity across PHQ-9 cut-
off scores for all participants from primary studies, 
as has been done in existing conventional meta-
analyses and, separately, among only participants 
who could be confirmed as not diagnosed as having 
or receiving treatment for a mental health problem at 
the time of assessment. We did this because existing 
conventional meta-analyses have all been based on 
primary studies that generally do not exclude patients 
already diagnosed as having or receiving treatment 
for a mental health problem. As screening is done to 
identify previously unrecognized cases, those patients 
would not be screened in practice, and their inclusion 
in diagnostic accuracy studies could bias results.10 11 
Thirdly, for each reference standard category, we 
estimated and compared sensitivity and specificity 
across PHQ-9 cut-off scores among subgroups 
based on age (<60 v ≥60 years), sex, country human 
development index (very high, high, low-medium), and 
recruitment setting (non-medical, primary, inpatient 
specialty, outpatient specialty). Among studies that 
used the MINI, we combined inpatient and outpatient 
specialty care settings, as only one study included 
inpatient participants. In each subgroup analysis, we 
excluded primary studies with no major depression 
cases, as this did not allow application of the bivariate 
random effects model. This resulted in a maximum of 
15 participants excluded from any subgroup analysis.
For each meta-analysis, for cut-off scores 5-15 
separately, bivariate random effects models were fitted 
via Gauss-Hermite adaptive quadrature.32 This two 
stage meta-analytic approach models sensitivity and 
specificity simultaneously, accounting for the inherent 
correlation between them and for precision of estimates 
within studies. For each analysis, this model provided 
estimates of pooled sensitivity and specificity.
To compare results across reference standards and 
other subgroups, we constructed empirical receiver 
operating characteristic curves for each group based 
on the pooled sensitivity and specificity estimates 
and calculated areas under the curve. We estimated 
differences in sensitivity and specificity between 
subgroups at each cut-off score by constructing 
confidence intervals for differences via the cluster 
bootstrap approach,33  34 resampling at study and 
participant levels. For each comparison, we ran 1000 
iterations of the bootstrap. We removed iterations that 
did not produce difference estimates for cut-off scores 
5-15 before determining confidence intervals and 
noted the number of iterations removed.
In addition to categorical subgroup analyses, 
we compared sensitivity and specificity across the 
different reference standards by doing one stage 
meta-regressions with interactions between reference 
standard category (reference category=semistructured 
interviews) and accuracy coefficients (logit(sensitivity) 
and logit(specificity)), and we compared results with 
those seen in the original two stage bivariate random 
effects meta-analytic models. Additionally, within each 
reference standard category, we did one stage meta-
regressions in which we interacted all subgrouping 
variables (age (measured continuously), sex (reference 
category=women), country human development 
index (reference category=very high), and participant 
recruitment setting (reference category=primary care)) 
with logit(sensitivity) and logit(specificity). Similarly 
to our main subgroup analyses, we again determined 
which significant interactions replicated across all three 
reference standard categories. For subgrouping variables 
that were significantly associated with sensitivity or 
specificity coefficients for all three reference standard 
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categories for all or most cut-off scores in the main one 
stage meta-regression, we did additional one stage 
meta-regression to produce accuracy estimates for the 
subgroups of interest, and we compared these results 
with those seen in the original two stage bivariate 
random effects meta-analytic models. Although age 
was included as a continuous variable in the main 
meta-regression, we again dichotomized it (<60 v ≥60 
years) to estimate accuracy and for comparison with the 
bivariate model results.
To investigate heterogeneity, we generated forest 
plots of sensitivities and specificities for cut-off 
score 10 for each study, first for all studies in each 
reference standard category and then separately across 
participant subgroups within each reference standard 
category. We quantified cut-off score 10 heterogeneity 
overall and across subgroups by reporting estimated 
variances of the random effects for sensitivity and 
specificity (τ2) and estimating R, the ratio of the 
estimated standard deviation of the pooled sensitivity 
(or specificity) from the random effects model to that 
from the corresponding fixed effects model.35 We 
used a complete case analysis, as complete data for 
all subgrouping variables were available for 17 357 
participants (98% of eligible participants in the 
database).
To estimate positive and negative predictive values 
using cut-off score 10 for different values of prevalence 
of major depression, we generated nomograms for each 
reference standard category by applying the cut-off 10 
sensitivity and specificity estimates from the meta-
analysis to hypothetical major depression prevalence 
values of 5-25%.
In sensitivity analyses, for each reference standard 
category, we compared accuracy results across 
subgroups based on Quality Assessment of Diagnostic 
Accuracy Studies-2 items for all items with at least 
100 cases of major depression among participants 
categorized as having “low” risk of bias and among 
participants with “high” or “unclear” risk of bias.
We did not do sensitivity analyses that combined 
accuracy results from individual participant data 
meta-analysis with published results from studies that 
did not contribute individual participant data because 
among the 14 eligible studies that did not contribute 
individual participant data, only two studies with a 
semistructured reference standard (total n=173, major 
depression n=29), one study with a fully structured 
reference standard (total n=730, major depression 
n=32), and one study using the MINI (total n=172, 
major depression n=33) published accuracy results 
eligible for this individual participant data meta-
analysis. The other studies had eligible datasets but 
did not publish eligible diagnostic accuracy results 
(supplementary table A).
For all analyses, we used R (R version R 3.4.1 and 
R Studio version 1.0.143) using the glmer function 
within the lme4 package, which uses one quatrature 
point. The only substantive deviations from our 
initial protocol were that we stratified accuracy 
results by reference standard category and did not do 
sensitivity analyses that combined accuracy results 
from individual participant data meta-analysis with 
published results from studies that did not contribute 
individual participant data.
Patient and public involvement
No patients were involved in setting the research 
question or the outcome measures, nor were 
they involved in developing plans for design or 
implementation of the study. No patients were asked 
to advise on interpretation or writing up of results. 
There are no plans to disseminate the results of the 
research to study participants or the relevant patient 
community.
Results
Search results and inclusion of primary datasets
Of 5248 unique titles and abstracts identified from 
the database search, 5039 were excluded after 
review of titles and abstracts and 113 after full text 
review, leaving 96 eligible articles with data from 
69 unique participant samples, of which 55 (80%) 
contributed datasets (supplementary figure A). 
Reasons for exclusion for the 113 articles excluded 
at full text level are given in supplementary table A. 
In addition, authors of included studies contributed 
data from three unpublished studies, for a total 
of 58 datasets (total n=17 357, major depression 
n=2312 (13%)). Characteristics of included studies 
and eligible studies that did not provide datasets are 
shown in supplementary table B. Excluding the three 
Table 1 | Participant data by diagnostic interview
Diagnostic interview No of studies No of participants No (%) with major depression
Semistructured:
 SCID 26 4733 785 (17)
 SCAN 2 1892 130 (7)
 DISH 1 100 9 (9)
Fully structured:
 CIDI 11 6272 554 (9)
 DIS 1 1006 221 (22)
 CIS-R 2 402 64 (16)
MINI 15 2952 549 (19)
Total 58 17 357 2312 (13)
CIDI=Composite International Diagnostic Interview; CIS-R=Clinical Interview Schedule-Revised; DIS=Diagnostic Interview Schedule; DISH=Depression 
Interview and Structured Hamilton; MINI=Mini International Neuropsychiatric Interview; SCAN=Schedules for Clinical Assessment in Neuropsychiatry; 
SCID=Structured Clinical Interview for DSM Disorders.
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unpublished studies, of 21 171 participants in 69 
eligible published studies, 16 956 (80%) participants 
from 55 included published studies were included.
Of 58 included studies, 29 used semistructured 
reference standards, 14 used fully structured reference 
standards, and 15 used the MINI (table 1). The SCID 
was the most common semistructured interview (26 
studies, total n=4733), and the CIDI was the most 
common fully structured interview (11 studies, total 
n=6272). Among studies that used semistructured, 
fully structured, and MINI diagnostic interviews, 
mean sample sizes were 232, 549, and 197, and mean 
numbers (percentages) with major depression were 32 
(14%), 60 (11%), and 37 (19%), respectively (table 2).
PHQ-9 accuracy by reference standard
Table 3 and table 4 show comparisons of sensitivity 
and specificity estimates by reference standard 
category. A cut-off score of 10 maximized combined 
sensitivity and specificity among studies using 
semistructured interviews (sensitivity 0.88, 95% 
confidence interval 0.83 to 0.92; specificity 0.85, 0.82 
to 0.88). Based on cut-off score 10, sensitivity and 
specificity were 0.70 (0.59 to 0.80) and 0.84 (0.77 to 
0.89) for fully structured interviews and 0.77 (0.68 
to 0.83) and 0.87 (0.83 to 0.90) for the MINI. Across 
cut-off scores, specificity estimates were similar across 
reference standards; however, sensitivity estimates for 
semistructured interviews were 5-22% higher than for 
fully structured interviews (median difference 18% at 
cut-off 10) and 2-15% higher than for the MINI (median 
difference 11% at cut-off 10). Receiver operating 
characteristic curves and area under the curve values 
are shown in supplementary figure B.
Heterogeneity analyses suggested moderate 
heterogeneity across studies, which improved in some 
instances when we considered subgroups. Cut-off 10 
sensitivity and specificity forest plots are shown in 
supplementary figure C, with τ2 and R values shown in 
supplementary table C.
Figure 1 shows nomograms of positive and negative 
predictive values for cut-off score 10 for each reference 
standard category. For hypothetical values of major 
depression prevalence of 5-25%, estimates of positive 
predictive values based on summary sensitivity 
and specificity values ranged from 24% to 66% for 
semistructured interviews, 19% to 59% for fully 
structured interviews, and 24% to 66% for the MINI; 
estimates of negative predictive values ranged from 
96% to 99% for semistructured interviews, 89% to 
98% for fully structured interviews, and 92% to 99% 
for the MINI.
When examined with meta-regression analysis, 
consistent with our main results, we found that PHQ-9 
sensitivity estimates for semistructured interviews were 
significantly higher than for fully structured interviews 
or the MINI (supplementary table D). The significant 
interactions corresponded to differences in sensitivity 
that across cut-off scores were 4-22% (median 18%) 
higher for semistructured interviews than for fully 
structured interviews and 1-16% (median 11%) higher 
for semistructured interviews than the MINI. Across 
all cut-off scores, the magnitude of the differences 
estimated on the basis of meta-regression were within 
1% of those estimated using the original two stage 
bivariate random effects meta-analytic models.
PHQ-9 accuracy among participants not diagnosed 
as having or receiving treatment for mental health 
problem
Sensitivity and specificity estimates were not 
statistically significantly different for any reference 
Table 2 | Participant data by subgroup
Participant  
subgroup
Semistructured diagnostic interviews Fully structured diagnostic interviews Mini International Neuropsychiatric Interview
No of 
studies No of participants
No (%) with 
 major  depression
No of 
studies No of participants
No (%) with 
 major  depression
No of 
studies No of participants
No (%) with 
 major  depression
All participants 29 6725 924 (14) 14 7680 839 (11) 15 2952 549 (19)
Participants not 
diagnosed as having or 
receiving treatment for 
mental health problem
20 2942 421 (14) 6 4161 306 (7) 6 927 168 (18)
Age <60 years 26 4132 629 (15) 14 5504 645 (12) 14 1958 310 (16)
Age ≥60 years 24 2577 295 (11) 10 2175 194 (9) 13 979 239 (24)
Women 28 3906 573 (15) 14 4285 463 (11) 15 1666 337 (20)
Men 25 2812 351 (12) 13 3395 376 (11) 15 1286 212 (16)
Very high country 
human development 
index
25 6195 739 (12) 9 5740 592 (10) 10 1924 430 (22)
High country human 
development index
4 530 185 (35) 2 326 61 (19) 3 542 61 (11)
Low-medium country 
human development 
index
– – – 3 1614 186 (12) 2 486 58 (12)
Non-medical care 2 567 105 (19) 2 963 74 (8) 2 299 72 (24)
Primary care 9 3163 377 (12) 5 3578 273 (8) 5 1290 168 (13)
Inpatient specialty care 8 867 121 (14) 2 372 34 (9) 1 137 25 (18)
Outpatient specialty 
care
12 2128 321 (15) 5 2767 458 (17) 7 1226 284 (23)
Some variables were coded at study level, and others were coded at participant level. Thus, number of studies does not always add up to total number in reference category.
 o
n
 18 April 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l1476 on 9 April 2019. Downloaded from 
RESEARCH
6 doi: 10.1136/bmj.l1476 | BMJ 2019;365:l1476 | the bmj
standard category when we restricted analyses to 
participants not currently diagnosed as having or 
receiving treatment for a mental health problem 
compared with all participants. See supplementary 
table E for results and supplementary figure D for 
receiver operating characteristic curves and area under 
the curve values.
PHQ-9 accuracy among subgroups
For each reference standard category, comparisons 
of sensitivity and specificity estimates based on 
bivariate models across PHQ-9 cut-off scores 5-15 
among subgroups based on age, sex, country human 
development index. and participant recruitment 
setting are shown in supplementary table E, with 
forest plots shown in supplementary figure C, receiver 
operating characteristic curves and area under the 
curve values in supplementary figure D, and τ2 and R 
values in supplementary table C.
Of the total of 484 categorical subgroup analyses 
that we did (22 subgroups × 11 cut-off thresholds for 
sensitivity and specificity) using the bivariate model, 
four comparisons excluded the null value of zero 
difference for cut-off scores 5-15. No comparisons that 
were significantly different in one reference standard 
category were statistically significant in either of the 
other two reference standard categories. Subgroup 
analyses are shown in supplementary table E.
In the meta-regression analyses, on the other hand, 
older age (measured continuously) was associated 
with higher specificity for all reference standards 
(supplementary table D). The significant interaction 
corresponded to specificity estimates that were 2-14% 
(median 6%) higher for participants aged 60 or over 
versus under 60 based on semistructured interviews, 
2-14% (median 8%) higher based on fully structured 
interviews, and 1-8% (median 5%) higher based on the 
MINI (supplementary table D). Across all cut-off scores, 
the magnitudes of the differences estimated on the 
basis of meta-regression with dichotomous age were 
within 2% of those estimated using the original two 
stage bivariate random effects meta-analytic models.
Risk of bias sensitivity analyses
Supplementary table F shows Quality Assessment 
of Diagnostic Accuracy Studies-2 ratings for each 
included primary study, and comparisons of PHQ-9 
accuracy across individual items for each reference 
standard category are shown in supplementary table 
E. For the item on blinding of the reference standard 
to PHQ-9 results, specificity was significantly greater 
for studies and participants with high or unclear risk 
Table 3 | Comparison of sensitivity and specificity estimates among semistructured versus fully structured reference standards
Cut-off 
score
Semistructured reference standard* Fully structured reference standard†
Difference across reference standards  
(semistructured minus fully structured)‡
Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI)
5 0.98 (0.96 to 0.99) 0.55 (0.49 to 0.60) 0.93 (0.87 to 0.97) 0.54 (0.43 to 0.64) 0.05 (−0.01 to 0.13) 0.01 (−0.13 to 0.16)
6 0.98 (0.95 to 0.99) 0.63 (0.58 to 0.67) 0.91 (0.83 to 0.95) 0.61 (0.51 to 0.71) 0.07 (−0.01 to 0.18) 0.02 (−0.12 to 0.17)
7 0.98 (0.94 to 0.99) 0.69 (0.65 to 0.74) 0.86 (0.75 to 0.92) 0.69 (0.59 to 0.77) 0.12 (0.00 to 0.26) 0.00 (−0.10 to 0.15)
8 0.95 (0.91 to 0.97) 0.75 (0.71 to 0.79) 0.82 (0.71 to 0.89) 0.75 (0.66 to 0.82) 0.13 (0.00 to 0.28) 0.00 (−0.10 to 0.13)
9 0.91 (0.87 to 0.94) 0.80 (0.77 to 0.83) 0.74 (0.63 to 0.83) 0.79 (0.72 to 0.86) 0.17 (0.05 to 0.34) 0.01 (−0.08 to 0.12)
10 0.88 (0.83 to 0.92) 0.85 (0.82 to 0.88) 0.70 (0.59 to 0.80) 0.84 (0.77 to 0.89) 0.18 (0.04 to 0.36) 0.01 (−0.05 to 0.12)
11 0.84 (0.78 to 0.89) 0.89 (0.86 to 0.91) 0.62 (0.51 to 0.72) 0.87 (0.81 to 0.91) 0.22 (0.07 to 0.40) 0.02 (−0.04 to 0.10)
12 0.79 (0.73 to 0.83) 0.91 (0.89 to 0.93) 0.57 (0.45 to 0.68) 0.89 (0.85 to 0.93) 0.22 (0.05 to 0.40) 0.02 (−0.03 to 0.09)
13 0.70 (0.65 to 0.75) 0.93 (0.91 to 0.95) 0.49 (0.38 to 0.61) 0.92 (0.89 to 0.95) 0.21 (0.04 to 0.40) 0.01 (−0.03 to 0.07)
14 0.64 (0.58 to 0.70) 0.95 (0.93 to 0.96) 0.44 (0.32 to 0.56) 0.94 (0.91 to 0.96) 0.20 (0.03 to 0.40) 0.01 (−0.02 to 0.05)
15 0.56 (0.50 to 0.62) 0.96 (0.95 to 0.97) 0.35 (0.25 to 0.46) 0.96 (0.93 to 0.97) 0.21 (0.05 to 0.39) 0.00 (−0.02 to 0.04)
*Studies n=29; participants n=6725; major depression n=924.
†Studies n=14; participants n=7680; major depression n=839.
‡1 bootstrap iteration (0.01%) did not produce difference estimate for cut-off score 5. This iteration was removed before bootstrapped CI was determined.
Table 4 | Comparison of sensitivity and specificity estimates among semistructured versus MINI reference standards
Cut-off 
score
Semistructured reference standard* MINI reference standard†
Difference across reference standards  
(semistructured minus MINI)
Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI) Sensitivity (95% CI) Specificity (95% CI)
5 0.98 (0.96 to 0.99) 0.55 (0.49 to 0.60) 0.96 (0.93 to 0.98) 0.57 (0.50 to 0.64) 0.02 (−0.02 to 0.07) −0.02 (−0.14 to 0.11)
6 0.98 (0.95 to 0.99) 0.63 (0.58 to 0.67) 0.93 (0.87 to 0.97) 0.66 (0.59 to 0.72) 0.05 (−0.01 to 0.12) −0.03 (−0.13 to 0.09)
7 0.98 (0.94 to 0.99) 0.69 (0.65 to 0.74) 0.90 (0.82 to 0.94) 0.72 (0.66 to 0.78) 0.08 (−0.00 to 0.16) −0.03 (−0.12 to 0.08)
8 0.95 (0.91 to 0.97) 0.75 (0.71 to 0.79) 0.86 (0.78 to 0.91) 0.78 (0.73 to 0.83) 0.09 (−0.01 to 0.19) −0.03 (−0.11 to 0.06)
9 0.91 (0.87 to 0.94) 0.80 (0.77 to 0.83) 0.82 (0.72 to 0.88) 0.84 (0.79 to 0.87) 0.09 (−0.02 to 0.22) −0.04 (−0.09 to 0.05)
10 0.88 (0.83 to 0.92) 0.85 (0.82 to 0.88) 0.77 (0.68 to 0.83) 0.87 (0.83 to 0.90) 0.11 (−0.01 to 0.25) −0.02 (−0.07 to 0.06)
11 0.84 (0.78 to 0.89) 0.89 (0.86 to 0.91) 0.70 (0.62 to 0.77) 0.90 (0.86 to 0.92) 0.14 (0.01 to 0.30) −0.01 (−0.06 to 0.05)
12 0.79 (0.73 to 0.83) 0.91 (0.89 to 0.93) 0.65 (0.56 to 0.72) 0.92 (0.89 to 0.94) 0.14 (−0.01 to 0.28) −0.01 (−0.05 to 0.05)
13 0.70 (0.65 to 0.75) 0.93 (0.91 to 0.95) 0.57 (0.49 to 0.65) 0.94 (0.91 to 0.96) 0.13 (−0.03 to 0.26) −0.01 (−0.04 to 0.04)
14‡ 0.64 (0.58 to 0.70) 0.95 (0.93 to 0.96) 0.49 (0.42 to 0.56) 0.96 (0.93 to 0.97) 0.15 (0.01 to 0.28) −0.01 (−0.04 to 0.03)
15‡ 0.56 (0.50 to 0.62) 0.96 (0.95 to 0.97) 0.42 (0.35 to 0.49) 0.97 (0.95 to 0.98) 0.14 (−0.01 to 0.27) −0.01 (−0.03 to 0.02)
MINI=Mini International Neuropsychiatric Interview.
*Studies n=29; participants n=6725; major depression n=924.
†Studies n=15; participants n=2952; major depression n=549.
‡For these cut-off scores, among studies that used MINI as reference standard, default optimizer in glmer failed, so bobyqa was used instead.
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versus low risk of bias for semistructured interviews 
but significantly greater for low risk versus high or 
unclear risk of bias for fully structured interviews 
and the MINI. For the item on recruiting a consecutive 
or random sample of participants, specificity was 
significantly greater for low risk versus high or unclear 
risk of bias for fully structured interviews and the MINI. 
We found no other statistically significant differences, 
and no significant differences were replicated across 
all reference standards.
Discussion
We compared the accuracy of scores on the PHQ-9 for 
screening to detect major depression, separately, with 
semistructured diagnostic interviews, fully structured 
diagnostic interviews (MINI excluded), and the MINI. 
Based on results from the semistructured interviews, 
which most closely replicate clinical interviews done 
by trained professionals, the PHQ-9 was more sensitive 
than has been reported in previous meta-analyses 
that combined reference standards.8  36 Specificity 
was similar to previous studies and across reference 
standards. Based on semistructured interviews, the 
standard cut-off score of 10 maximized combined 
sensitivity and specificity. We found evidence from 
multivariable meta-regression that the PHQ-9 may 
be more sensitive among older patients than younger 
patients, but this would not require that a different cut-
off score be used. Results did not differ depending on 
whether studies that did not explicitly exclude patients 
already diagnosed as having depression were included 
or excluded. Among studies conducted in primary care 
settings, approximately half of patients who screened 
positive on the PHQ-9 had major depression.
Findings in context
This is the first meta-analysis that has analyzed 
diagnostic accuracy for the PHQ-9 separately 
for different diagnostic interviews. Diagnostic 
interviews that are used to classify case status for 
major depression are imperfect reference standards. 
Semistructured interviews, such as the SCID,13 most 
closely approximate an expert diagnosis. They are 
set up to replicate a guided diagnostic conversation 
with standardized questions, with the option for 
interviewers to make additional queries and use clinical 
judgment to decide whether symptoms are present.16 17 
Semistructured interviews involve lengthy processes 
that must be conducted by skilled diagnosticians 
and, thus, are expensive. Fully structured interviews, 
such as the CIDI,14 are designed to replicate as closely 
as possible expert administered semistructured 
interviews but are not expected to have the same level of 
validity and reliability. Fully structured interviews can 
be administered by lay interviewers and involve fully 
scripted standardized interview protocols that are read 
verbatim without additional probes or interpretation. 
Fully structured interviews are designed to increase 
reliability with administration by lay interviewers 
who are not trained to carry out diagnostic interviews 
independently at the possible cost of validity.16  17 
The MINI is a specific fully structured interview that 
was designed to be administered in a fraction of the 
time compared with other interviews and described 
by its developers as intentionally overinclusive.19  20 
Test-retest reliability for diagnosis of current major 
depression has been reported to be κ=0.74 for the SCID 
(n=51; mean 9 days)37 and κ=0.52 for the CIDI (n=60; 
mean 2 days).38
Consistent with the design features and rigor of each 
type of diagnostic interview, we previously reported 
that compared with semistructured interviews, fully 
structured interviews (excluding the MINI) classify 
more people with low symptoms as having major 
depression but fewer people with high symptoms.12 We 
also found that the MINI identified approximately twice 
as many cases as other fully structured interviews.12 The 
finding in this study that sensitivity was greater among 
studies with semistructured than fully structured 
reference standards is consistent with both the design 
features and rigor of the different types of diagnostic 
interviews and with our previous findings. The lower 
sensitivity among fully structured interviews may have 
been due to overdiagnosis of major depression among 
participants with low depressive symptom levels when 
fully structured interviews were used. In this meta-
analysis, most participants (87%) did not have major 
depression, so misclassification of major depression 
among participants with subthreshold depressive 
symptom levels based on fully structured interviews 
might explain the lower sensitivity compared with 
semistructured interviews if the PHQ-9 were less 
P
os
it
iv
e 
pr
ed
ic
ti
ve
 v
al
u
e
0
0.4
0.6
0.8
0.2
Major depression prevalence (%)
N
eg
at
iv
e 
pr
ed
ic
ti
ve
 v
al
u
e
0.80
0.90
0.95
1.00
0.85
5 10 15 20 25
Semistructured
Fully structured
MINI
Fig 1 | Nomograms of positive (top) and negative (bottom) 
predictive values for cut-off score 10 of the Patient 
Health Questionnaire-9 (PHQ-9) for major depression 
prevalence values of 5-25% for each reference standard 
category (semistructured diagnostic interviews, fully 
structured diagnostic interviews, and Mini International 
Neuropsychiatric Interview (MINI))
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likely to identify “false positive” classifications based 
on fully structured interviews. The same logic would 
apply to the lower sensitivity for the MINI.
Among studies that used semistructured reference 
standards, sensitivity was also greater than reported 
in previous traditional meta-analyses, in which studies 
with semistructured and fully structured reference 
standards and the MINI were combined without 
adjustment. Using individual participant data from 
the 29 studies that used a semistructured interview as 
the reference standard, we found that at a cut-off score 
of 10, sensitivity and specificity were 0.88 and 0.85 
compared with 0.78 and 0.87 in a 2015 conventional 
meta-analysis of 34 studies that combined reference 
standards.8 In primary care settings, we found 
sensitivity and specificity of 0.94 and 0.88 (nine studies 
with a semistructured interview) compared with 0.82 
and 0.85 in a 2016 conventional meta-analysis of 20 
studies that combined reference standards.36
For semistructured interviews, prevalence of major 
depression in our dataset was 14%. Using our cut-off 10 
accuracy estimates (sensitivity 0.88, specificity 0.85), 
the positive predictive value would be only 49%; thus 
51% of all positive screens would be false positives. 
For primary care settings, where accuracy was even 
higher, prevalence of major depression was 12%. 
Using our accuracy estimates for cut-off 10 (sensitivity 
0.94, specificity 0.88, positive predictive value 52%), 
22% of patients in primary care would screen positive 
at this cut-off score, but only approximately half would 
be true positives.
To facilitate understanding for clinicians considering 
use of the PHQ-9 to screen for depression, we have 
developed a web based tool (depressionscreening100.
com/phq). The tool can be used to estimate the 
expected number of positive screens and true and false 
screening outcomes based on results from this study.
Clinical implications
Screening for depression in primary care is 
recommended in the US,39 but national guidelines from 
Canada and the UK advise against routine screening 
for depression.40  41 Those guidelines cite the lack of 
evidence of benefit from well conducted randomized 
controlled trials, as well as concerns about high false 
positive rates, overdiagnosis, and substantial resource 
use and opportunity costs.40  41 Well conducted and 
adequately powered trials designed specifically 
to assess the effects of depression screening are 
needed.12 40-43 If screening is to be done clinically on 
the basis of recommendations in the US, the cut-off 
score that maximizes sensitivity and specificity is the 
standard cut-off of 10 or greater. Whether using this 
standard cut-off score would maximize the likelihood 
that screening would successfully improve mental 
health and minimize unnecessary resource use and 
adverse outcomes if tested in a trial is, however, not 
known. Ideally, robust trials that are sufficiently 
powered to evaluate the effects of screening across a 
range of cut-off scores will be conducted. Clinical trials 
provide the best possible evidence to inform both the 
decision on whether depression screening should be 
implemented as part of routine care and, if so, the 
thresholds for intervening or what steps might be 
taken for patients with borderline screening results.44
Strengths and limitations of study
This was the first study to use individual participant 
data meta-analysis to assess diagnostic accuracy of the 
PHQ-9 or any other depression screening tool. Strengths 
include the large sample size, the ability to include 
results from all cut-off scores from all studies (rather 
than just those published), the ability to examine 
subgroups of participants, and the ability to assess 
accuracy separately across reference standards, which 
had not been done previously. Some limitations should 
also be considered. Firstly, we were unable to include 
primary data from 14 of 69 published eligible datasets 
(20% of eligible datasets and participants), and we 
restricted our analyses to those with complete data 
for all variables used in our various analyses (98% of 
available data). Nevertheless, for all cut-off scores other 
than 10, our sample was much larger than previous 
traditional meta-analyses of the PHQ-9. Secondly, 
despite the large sample size, substantial heterogeneity 
existed across studies, although it improved in some 
instances when we considered subgroups. We were 
not able to do subgroup analyses based on specific 
medical comorbidities or cultural aspects such as 
country or language, because comorbidity data were 
not available for more than half of participants and 
many countries and languages were represented 
in few primary studies. However, we were able to 
compare participant subgroups based on age, sex, 
country human development index, and participant 
recruitment setting category, which has not been done 
previously. Thirdly, although we categorized studies 
on the basis of the diagnostic interview administered, 
interviews are sometimes adapted and thus not always 
used in the way that they were originally designed. 
Although we coded for qualifications of interviewer 
for all semistructured interviews as part of our Quality 
Assessment of Diagnostic Accuracy Studies-2 rating, 
two studies used interviewers who did not meet typical 
standards, and approximately half of studies were 
rated as unclear on this item.
Although our original two stage bivariate random 
effects meta-analytic models did not find significant 
differences in accuracy estimates across participant 
subgroups, our meta-regressions suggested that 
specificity might be somewhat higher among older 
participants whether measured continuously or 
dichotomously. This difference in significance may 
be due to the differences between the analytical 
approaches. Whereas statistical significance of the 
interactions between covariates and accuracy estimates 
in the meta-regressions were based on parametric 
standard errors, statistical significance of subgroup 
comparisons in the two stage bivariate random effects 
models was based on non-parametric bootstrap 
methods. Moreover, whereas the meta-regression 
models provide a within study interpretation, the two 
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stage bivariate random effects models did not link 
study clusters across subgroups and thus focused more 
on between study comparisons.
Conclusions and policy implications
In summary, we found that the sensitivity of PHQ-9 
compared with semistructured reference standards 
was substantially greater than when compared with 
fully structured reference standards or the MINI. 
It was also substantially higher than previously 
reported in conventional meta-analyses that combined 
reference standards.8  36 The standard cut-off score 
of 10 or greater maximized combined sensitivity and 
specificity. However, in primary care, approximately 
half of patients with positive screens would be false 
positives if this was used in practice, a concern that 
has been emphasized by the Canadian Task Force 
on Preventive Health Care, UK National Screening 
Committee, and UK National Institute for Health and 
Care Excellence, given the resources that would be 
needed for additional assessment and the possibility 
that some of these patients might be treated without 
benefit.40  41  43 Future research on the PHQ-9 should 
ideally be based on semistructured diagnostic 
interviews, should consider estimating probabilities of 
depression across the full spectrum of PHQ-9 screening 
scores (rather than dichotomizing scores at a cut-off), 
and should combine screening scores with individual 
characteristics to generate individualized probabilities 
of major depression.
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